Table 2:

Demographic and clinical characteristics of patients with MS with comorbidities, according to their specific comorbidity type

DiseaseFemales (No.) (%)Age (yr) (Mean) (SD)DD (yr) (Mean) (SD)EDSS (Median) (IQR)MS Subtype (No.) (%)DMT Use (No.) (%)DMT Months (Mean) (SD)
RRSPPP
Asthma (n = 41)38 (92.7)45.2 (8.8)12.4 (10.0)2.5 (1.5–5.0)32 (78)7 (17.1)2 (4.9)32 (78.0)51.7 (40.7)
Crohn disease (n = 1)1 (100)53163.00 (0)1 (100)0 (0)1 (100)60
Diabetes mellitus type 1 (n = 3)2 (66.6)36.3 (4.7)6.7 (4.2)2.3 (1.5–2.5)2 (66.7)1 (33.3)0 (0)0 (0.0)0 (0)
Diabetes mellitus type 2 (n = 40)28 (70.0)49.3 (8.7)14.5 (9.9)5.5 (2.0–5.0)23 (57.5)16 (40)1 (2.5)29 (72.5)50.9 (40.7)
Myasthenia gravis (n = 1)1 (100)47126.50 (0)1 (100)0 (0)1 (100)24
Psoriasis (n = 33)23 (69.7)50.4 (9.1)15.9 (10)3.0 (2.0–5.5)21 (63.6)11 (33.3)1 (3.1)24 (72.7)63.7 (34.2)
Rheumatoid arthritis (n = 22)17 (77.3)51.8 (9.1)16.4 (11.8)3.0 (1.5–5.5)13 (59.1)8 (36.4)1 (4.5)17 (77.2)58.4 (31.4)
SLE (n = 3)2 (66.6)50 (3)15.7 (1.5)4.0 (4.0–5.0)0 (0)3 (100)0 (0)3 (100)50.3 (24.6)
Thyroid disease (n = 97)89 (91.8)46.6 (10.6)14.6 (11.1)2.5 (1.5–5.5)66 (68.0)29 (29.9)2 (2.1)68 (70.1)46.5 (35.2)
  • Note:—SLE indicates systemic lupus erythematosus; DD, disease duration; RR, relapsing-remitting; SP, secondary-progressive; PP, primary-progressive; DMT, disease-modifying therapy; IQR, interquartile range.